# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Rachel Carson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML041-SYN
- Date: 2026-09-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Vance-Okonkwo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Monitoring visit at the start of the fourth ribociclib cycle. **S**

## History of present illness

Ms. Carson is twelve weeks into letrozole and starts her fourth cycle of ribociclib today. The oncology blood tests at about day 14 of the first cycle and on schedule since have shown neutrophils between 1.3 and 1.7, with normal liver tests and electrolytes; the neutrophil count was 1.2 at her sick visit in July, without fever, and she has had no fever since. The ECG planned for about day 14 of the first cycle was not done: she was away on the coast that week for field work and the ECG was not rebooked with her blood test. It was done at the start of the second cycle, four weeks after starting: QTcF 426 ms. She has mild morning knee stiffness for about ten minutes, eased by walking, and occasional night hot flashes. She is finishing the draft of her book this month. **S**

| Element | Detail |
|---|---|
| Interval change | Cycles 1 to 3 of ribociclib completed at full dose; viral rhinosinusitis in July |
| Oncology results | Neutrophils 1.3 to 1.7; liver tests and electrolytes normal; QTcF 426 ms at the start of cycle 2 |
| Side effects | Mild knee stiffness and night hot flashes |
| Adherence | No missed doses by her diary |
| Work | Finishing the draft of her book |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy good |
| Cardiovascular | Negative | No palpitations, fainting, or chest pain |
| Gastrointestinal | Negative | No nausea, diarrhea, or indigestion |
| Musculoskeletal | Positive | Morning knee stiffness for about ten minutes; no bone pain |
| Genitourinary | Negative | No vaginal bleeding |
| Integumentary | Negative | No rash; radiation skin settled |
| Psychiatric | Negative | Mood good; PHQ-9 3 |

7 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a day **S**
- Letrozole 2.5 mg oral tablet, one tablet by mouth once daily, planned for at least five years **S**
- Ribociclib 200 mg oral tablet, two tablets (400 mg) by mouth once daily on days 1 to 21 of each 28-day cycle, with letrozole, planned for three years **S**
- Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every six months for three years **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 59.6 kg; BMI 22.4 kg/m². All vital signs are synthetic.

Hemoglobin: 12.5 g/dL; White cell count: 3.4 10*3/uL (low); Absolute neutrophil count: 1.6 10*3/uL (low); Platelets: 192 10*3/uL; Creatinine: 0.8 mg/dL; ALT: 31 U/L; AST: 29 U/L; Total bilirubin: 0.7 mg/dL; Potassium: 4.1 mmol/L; Magnesium: 2 mg/dL; Calcium: 9.5 mg/dL; 25-hydroxyvitamin D: 34 ng/mL; PHQ-9: 3. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.3 g/dL at baseline, 12.5 g/dL at this visit **S**
- White cell count: 6.4 10*3/uL at baseline, 3.4 10*3/uL (low) at this visit **S**
- Platelets: 262 10*3/uL at baseline, 192 10*3/uL at this visit **S**
- Creatinine: 0.8 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- ALT: 18 U/L at baseline, 31 U/L at this visit **S**
- AST: 20 U/L at baseline, 29 U/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Breasts | Left breast mildly firm after radiation; no masses. Right breast normal |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes |
| Extremities | Arm circumference 25.5 cm on each side; knees with mild crepitus and no effusion |
| Abdomen | Soft; liver not enlarged |
| Eyes | No jaundice |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Letrozole with ribociclib, start of cycle 4** (Z79.811). Neutrophils 1.6 today (grade 1), liver tests normal (ALT 31, AST 29, bilirubin 0.7), electrolytes normal; QTcF 426 ms at four weeks. Ribociclib continues at full dose. The missed day-14 ECG is recorded as a protocol deviation; the four-week ECG was normal, so no harm resulted. **S**
   - Continue letrozole and ribociclib at the same doses.
   - Blood count, liver tests, and electrolytes at the start of cycles 5 and 6.
   - Any new medicine checked against her QT and interaction list first.
2. **Knee osteoarthritis with mild aromatase inhibitor joint symptoms** (M17.0). Morning stiffness slightly longer than before letrozole but mild; walking helps. **S**
   - Daily walking and strength exercises; acetaminophen as needed.
   - Report if pain limits walking; options then include duloxetine or a break from letrozole with the oncology team.
3. **Low bone mass on zoledronic acid** (M85.80). Vitamin D 34 ng/mL on replacement; calcium 9.5. **S**
   - Second zoledronic acid infusion in December.
   - Continue vitamin D3.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count on ribociclib | Every 2 weeks for 2 cycles, then at the start of the next 4 cycles | Completed today | White cells 3.4, neutrophils 1.6 (grade 1), hemoglobin 12.5, platelets 192; earlier oncology counts 1.3 to 1.7 |
| Laboratory | Liver tests on ribociclib | Every 2 weeks for 2 cycles, then at the start of the next 4 cycles | Completed today | ALT 31, AST 29, bilirubin 0.7; all earlier results normal |
| Laboratory | Electrolytes on ribociclib | At the start of each of the first 6 cycles | Completed today | Potassium 4.1, magnesium 2.0, calcium 9.5 |
| Medication safety | ECG at about day 14 of the first cycle | Day 14 of cycle 1 | Deferred | Missed, a deviation from the protocol: she was away for field work and the ECG was not booked with her blood test. It was done at the start of cycle 2 instead, QTcF 426 ms, normal, so no harm resulted. Corrective action: the oncology scheduler now books ECGs with the blood tests and confirms by telephone; any dose change or new QT-prolonging drug will prompt a repeat ECG |
| Medication safety | Interaction review | With every new medicine | Completed today | No new medicines; the July illness was treated without antibiotics |
| Medication safety | Zoledronic acid: kidney function before the next infusion | Before each infusion | Completed today | Creatinine 0.8; next infusion in December |
| Laboratory | Calcium and vitamin D adequacy | Ongoing on an aromatase inhibitor | Completed today | 25-hydroxyvitamin D 34 ng/mL on replacement |
| Examination | Aromatase inhibitor joint pain and musculoskeletal review | Every visit | Completed today | Mild morning knee stiffness, slightly longer than at baseline |
| Survey | Vasomotor and vaginal symptoms | Periodically on endocrine therapy | Completed today | Occasional night hot flashes; no treatment wanted |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | 25.5 cm on each side; no swelling |
| Examination | Cancer-related history and physical examination | Every 3 to 6 months for the first 3 years | Completed today | No signs of recurrence |
| Survey | Depression screen (PHQ-9) | At periodic intervals | Completed today | PHQ-9 3 |
| Imaging | Mammogram after breast-conserving treatment | 6 to 12 months after radiation, then yearly | Due | From late November |
| Laboratory | Routine tumor markers and body imaging | Not recommended without symptoms | Not indicated | None ordered |
| Self-management | Activity, alcohol, and work | Every visit | Completed today | Walking about 150 minutes a week; rare alcohol; writing most mornings |

## Goal progress

- Receive the biopsy result in person within ten days, explained in plain words, with a copy of the report. Outcome by 2026-03-18: Told the diagnosis in person nine days after presentation, with the pathology report in hand; teach-back confirmed her understanding. **S**
- Make each treatment decision herself after hearing the options, benefits, and harms. Outcome by 2026-04-20: Chose breast-conserving surgery and, after the pathology, radiation, letrozole, ribociclib, and zoledronic acid. **S**
- Complete surgery and radiation, then start endocrine therapy, within four months of diagnosis. Outcome by 2026-06-15: Lumpectomy at three weeks, radiation completed at ten weeks, letrozole and ribociclib started at thirteen weeks. **S**
- Take adjuvant systemic therapy safely, with every safety check the drugs require done on schedule. In progress; target 2026-12-07. **S**
- Keep writing at least four mornings a week through treatment. In progress; target 2026-12-07. **S**

## Guideline basis

- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019), American Society of Clinical Oncology
- Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2024;42(18):2233-2235 (2024), American Society of Clinical Oncology
- KISQALI (ribociclib) tablets: prescribing information (dosage for early breast cancer; QT, hepatotoxicity, and neutropenia monitoring) (2026), U.S. National Library of Medicine, DailyMed
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 2022;40(7):787-800 (2022), American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario)
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge

## Follow-up

- Oncology blood tests at the start of cycles 5 and 6. Adult preventive visit next month. Zoledronic acid in December. Mammogram from late November. **S**
- Next scheduled visit 2026-10-13: adult preventive visit. **S**
